This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation
Leukemia Open Access 08 August 2018
-
New drug approvals in acute myeloid leukemia: what’s the best end point?
Leukemia Open Access 18 December 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ferrara F, Schiffer CA . Acute myeloid leukaemia in adults. Lancet 2013; 381: 484–495.
Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 2015; 29: 312–320.
Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079–1089.
Gönen M, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood 2012; 120: 2297–2306.
Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249–1259.
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29: 4417–4423.
Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642–4649.
Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol 2014; 32: 548–556.
Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 2013; 31: 2086–2093.
Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090–1098.
Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A et al. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 2007; 110: 4172–4174.
Lacombe F, Arnoulet C, Maynadié M, Lippert E, Luquet I, Pigneux A et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia 2009; 23: 350–357.
Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013; 31: 3889–3897.
Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31: 4123–4131.
Acknowledgements
Research reported in this publication was supported by grants from the National Cancer Institute/National Institutes of Health (NCI/NIH; R21-CA182010 to RBW and MO, and R01-CA090998-09 to MO). The E1900 study was conducted by the ECOG-ACRIN Cancer Research Group (Robert L Comis, and Mitchell D Schnall, group co-chairs) and supported in part by Public Health Service Grants CA180820, CA180794, CA189859, CA180867, and CA180791 from the NCI/NIH and the Department of Health and Human Services. RBW is a Leukemia and Lymphoma Society Scholar in Clinical Research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Walter, R., Othus, M., Paietta, E. et al. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia 29, 2104–2107 (2015). https://doi.org/10.1038/leu.2015.76
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.76
This article is cited by
-
Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation
Leukemia (2019)
-
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials
Leukemia (2019)
-
Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission
Bone Marrow Transplantation (2019)
-
Refining AML outcome prediction
Leukemia (2019)
-
How good are we at predicting the fate of someone with acute myeloid leukaemia?
Leukemia (2017)